2025 Summit on Innovations in Controlled Release, Bioavailability Enhanceme

• Significance of Multiparticulates
• Leveraging Multiparticulates for Customized Release
• Adare's Multiparticulates-based Technology - Diffucaps®
• Case Studies

Dr. Shahab Kashani Rahimi is the lead principal scientist in
the product development team at Ardena. Shahab has 7
years of experience in pharmaceutical oral solid and liquid
formulation and manufacturing process development, and his
work focuses on solubility/bioavailability enhancement
technologies including hot melt extrusion and spray drying,
development of immediate and modified release dosage
forms and novel complex drug delivery systems. His
experience spans all stages of product development, from
pre-clinical development and proof of concept to scale-up, clinical and registration
manufacturing. Shahab holds a PhD in polymer science and engineering and has
previously worked as a formulation principal scientist at Catalent Pharma Solutions and
BioDuro and as a postdoctoral research fellow at molecular pharmaceutics and drug
delivery department at University of Texas at Austin.

Modified release (MR) drug delivery systems play a critical role in optimizing therapeutic outcomes, improving patient compliance, and extending product lifecycles. This presentation explores a comprehensive, science-driven approach to MR formulation development, integrating modern modeling tools, robust technology platforms, and strategic development methodologies.
The session will highlight the role of physiologically based pharmacokinetic (PBPK) modeling in assisting formulation design, enabling prediction of in vivo performance and supporting accelerated development with minimal pharmacokinetic study iterations. The use of biorelevant and predictive dissolution methods to establish in vitro-in vivo correlations (IVIVC) that reduce development time and risk will also be discussed.
A broad spectrum of modified release technologies will be discussed, including matrix-based systems (erodible and diffusion-controlled), multiparticulates, bilayer tablets, osmotic tablets, and controlled-release of amorphous solid dispersions.
Each technology will be evaluated in terms of its ability to meet specific pharmacokinetic profiles, align with the Quality Target Product Profile (QTPP), and fulfill therapeutic goals. The presentation will explore how to select the most cost-effective technology without compromising performance, guided by a Quality by Design (QbD) framework that ensures a scientifically sound and risk-managed development strategy.
Attendees will gain insight into rational technology selection, efficient formulation pathways, and how MR systems can be leveraged not only to improve patient outcomes but also to strategically position products throughout their lifecycle.

With about 20 worldwide approvals and almost a decade of commercial applications, CM is fertile ground for the next generation of implementation. Progress in the next few years will be fueled by major competitive advantages of CM:
- The faster speed in development of new products and processes enabled by CM will make it a central technology in pharmaceutical reshoring.
- The greater ability to model and control CM processes and improve quality control provides a major opportunity for the implementation of advanced manufacturing methodologies aligning closely with the FDA AMT designation program, enabling faster review of NDAs, ANDAs, and PAS.
- New formulation methods for continuous direct compression enable major reductions in the effort and materials required to develop or transfer manufacturing processes